Coskun, H. Ş. Et Al. 2008. Bleomycin, etoposide and cisplatin (BEP) combination with concurrent imatinib mesylate (GLEEVEC) in chronic myeloid leukemia (CML) patient with mesenchymal tumor.. Medical oncology (Northwood, London, England) , vol.25, no.1 , 110-2.

Coskun, H. Ş., Goeksu, S., ŞAHİN, M., & Alanoglu, G., (2008). Bleomycin, etoposide and cisplatin (BEP) combination with concurrent imatinib mesylate (GLEEVEC) in chronic myeloid leukemia (CML) patient with mesenchymal tumor.. Medical oncology (Northwood, London, England) , vol.25, no.1, 110-2.

Coskun, HASAN Et Al. "Bleomycin, etoposide and cisplatin (BEP) combination with concurrent imatinib mesylate (GLEEVEC) in chronic myeloid leukemia (CML) patient with mesenchymal tumor.," Medical oncology (Northwood, London, England) , vol.25, no.1, 110-2, 2008

Coskun, HASAN Ş. Et Al. "Bleomycin, etoposide and cisplatin (BEP) combination with concurrent imatinib mesylate (GLEEVEC) in chronic myeloid leukemia (CML) patient with mesenchymal tumor.." Medical oncology (Northwood, London, England) , vol.25, no.1, pp.110-2, 2008

Coskun, H. Ş. Et Al. (2008) . "Bleomycin, etoposide and cisplatin (BEP) combination with concurrent imatinib mesylate (GLEEVEC) in chronic myeloid leukemia (CML) patient with mesenchymal tumor.." Medical oncology (Northwood, London, England) , vol.25, no.1, pp.110-2.

@article{article, author={HASAN ŞENOL COŞKUN Et Al. }, title={Bleomycin, etoposide and cisplatin (BEP) combination with concurrent imatinib mesylate (GLEEVEC) in chronic myeloid leukemia (CML) patient with mesenchymal tumor.}, journal={Medical oncology (Northwood, London, England)}, year=2008, pages={110-2} }